Professor Chris Fegan qualified in Newcastle and trained in haematology in the West Midlands and Cardiff before taking up his current consultant post at Cardiff in 2005. He has a long standing clinical and research interest in CLL, in particular in apoptosis and new drug development. His research spans the role of CD38, NF kappa-B, telomeres, CLL cell migration and T-cell specific responses in CLL.
He is currently principal or chief investigator on 12 clinical trials including four phase I studies. He is a member of the Guidelines and Clinical Trials Committees of the UK CLL Forum, as well as a former Treasurer.
Chris has published over 160 papers to date in peer reviewed journals, as well as contributing chapters in haematology textbooks and internet sites. He is currently Director of Research and Development in Cardiff, Chairman of the Haematology National Strategy Advisory Group in Wales and a regular expert medical advisor to NICE and medical advisor to the charities Chronic Blood Cancer Support Group and Leukaemia Care.